BRAF and melanoma: Because resistance to BRAF inhibitors in melanoma patients is almost always due to reactivation of the MAP Kinase pathway [6, 11, 13, 15, 18, 20, 44, 60, 70, 84, 86–96] we expected that lapatinib would reinforce the effectiveness of PLX4720 on MAP Kinase pathway inhibition.